B-Cell Malignancies Clinical Trial
Official title:
A Phase I, First-In-Human, Multicenter, Open Label, and Dose-Escalation Study of TT-01488, Administered Orally in Adult Patients With B-Cell Malignancies
This is a first-in-human (FIH), multicenter, open-label Phase I dose escalation study to evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK inhibitor, for the treatment of adult patients with B-cell malignancies.
The study will consist of two parts, dose escalation and dose expansion. A modified 3+3 design will be used to guide the dose escalation and the determination of the dose recommended for dose expansion (DRDE). A sentinel cohort comprising of one subject will be enrolled at a starting dose of 50 mg q.d. Subsequently, patients will be enrolled according to the standard 3+3 dose escalation design to determine the DRDE. Once the DRDE has been selected, TT-01488 of DRDE will be further tested in the dose expansion cohort to verify the safety and preliminary efficacy as observed in the dose escalation cohorts. A recommended Phase II dose (RP2D) may be determined based on the totality of safety, pharmacokinetics, and efficacy data from the dose escalation cohorts and dose expansion cohort. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02343120 -
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT02018861 -
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
|
Phase 1/Phase 2 | |
| Terminated |
NCT03701438 -
Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
|
||
| Completed |
NCT02327078 -
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
|
Phase 1/Phase 2 | |
| Completed |
NCT04551963 -
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT05683717 -
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
|
Phase 1 | |
| Completed |
NCT01775631 -
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT01905813 -
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT02457598 -
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT03050190 -
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03125577 -
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04170283 -
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
|
Phase 3 | |
| Recruiting |
NCT04509700 -
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
|
Phase 2 | |
| Not yet recruiting |
NCT03642496 -
Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies
|
Early Phase 1 | |
| Completed |
NCT00983619 -
A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies
|
Phase 1/Phase 2 |